Krystal Biotech reported second quarter 2026 financial results on August 3, 2026. The company generated $119.2 million in net product revenue from its gene therapy VYJUVEK, a 24% increase year-over-year, with gross margins of 95%. Net income reached $54.8 million, or $1.79 per diluted share, compared to $38.3 million previously. The company ended the quarter with $1.1 billion in cash and investments. VYJUVEK launches are progressing in Germany, France, and Japan, with pricing discussions ongoing in Europe and expected commercial launches in Italy and Spain before year-end. The pipeline includes registrational data readouts for KB803 in 4Q 2026 and enrollment completion for KB801 and KB407 by year-end. Krystal Biotech is a biotechnology company focused on the discovery, development, and commercialization of genetic medicines.

Krystal Biotech, Inc. disclosed a single-patient observation from a discontinued clinical study for KB801, an investigational gene therapy for neurotrophic keratitis, following a response to a USPTO Office Action. The patient experienced complete closure of a persistent corneal epithelial defect. Krystal Biotech, Inc. is a biotechnology company developing gene therapies.